You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/refractory to JAKi

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Jul 31, 2023

Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))

Not yet recruiting
  • Refractory Cancer
  • Relapsed Cancer
  • Drug Sensitivity Test (DST)
  • Weston, Florida
    Lerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

    Available
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Mar 6, 2023

    Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Relmacabtagene Autoleucel Injection
    • (no location specified)
    Apr 13, 2023

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Oct 30, 2023

    Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • YTS104 Cells injection
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jun 13, 2023

    Light Chain Amyloidosis Trial (FKC288)

    Not yet recruiting
    • Light Chain Amyloidosis
    • (no location specified)
    Jul 30, 2023

    Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)

    Recruiting
    • Refractory Solid Tumors
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • ISB 2001
    • Benowa, Queensland, Australia
      Pindara Private Hospital
    May 18, 2023

    Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

    Available
    • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
    • Relapsed/Refractory Acute Myeloid Leukemia
    • Magrolimab
    • (no location specified)
    Jan 18, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Sep 20, 2023

    Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

    Not yet recruiting
    • Relapsed or Refractory T-cell Lymphomas
    • Sendai-shi, Miyagi, Japan
      Local Institution - 0001
    Sep 12, 2023

    Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

    Not yet recruiting
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Beijing, China
    • +3 more
    Jul 20, 2023

    Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

    Recruiting
    • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
    • thiotepa combined with pomalidomide
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital.
    Jun 27, 2023

    Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

    Recruiting
    • Acute Myeloid Leukemia Refractory
    • Acute Myeloid Leukemia, in Relapse
    • anti Tim-3/CD123 CAR-T cell therapy
    • Xuzhou, Jiangsu, China
      Kailin Xu
    Nov 4, 2023

    Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Relapsed/Refractory B-Cell Lymphoma
    • (no location specified)
    Jul 10, 2023

    Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
    • (no location specified)
    Sep 5, 2023

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

    Not yet recruiting
    • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
    • (no location specified)
    Jun 28, 2023

    SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • +2 more
      • (no location specified)
      Jun 22, 2023